U.S. markets open in 2 hours 41 minutes

Avalo Therapeutics, Inc. (AVTX)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
4.6000+0.1800 (+4.07%)
At close: 03:59PM EST
4.6100 +0.01 (+0.22%)
Pre-Market: 06:28AM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close4.4200
Bid0.0000 x 1000
Ask0.0000 x 1100
Day's Range4.4200 - 4.6499
52 Week Range3.9500 - 1,130.4000
Avg. Volume89,960
Market Cap3.687M
Beta (5Y Monthly)0.69
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for AVTX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Avalo Therapeutics, Inc.
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more
  • GlobeNewswire

    Avalo Therapeutics Announces 1-for-240 Reverse Stock Split

    WAYNE, Pa. and ROCKVILLE, Md., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced a 1-for-240 reverse stock split of the Company’s common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time on December 28, 2023. The Company’s common stock will trade on the Nasdaq Capital Market on a split-adjusted basis beginning on December 29, 2023, under the Company’s existing trading symbol “AVTX”. The Company is implementing the reverse stock split

  • GlobeNewswire

    Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split

    Annual Meeting has been adjourned until December 20, 2023Most stockholders can vote via or by calling 1-800-690-6903. If you have any questions about how to vote, please call 1-800-607-0088 WAYNE, Pa. and ROCKVILLE, Md., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) encourages its stockholders to participate actively in the upcoming adjourned annual meeting of stockholders, initially convened on December 5, 2023, and scheduled to reconvene on Wednesday,

  • GlobeNewswire

    Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates

    Successfully eliminated $35 million debt paving the way for future growth and innovationDivested AVTX-800 series for potential milestone payments of $45 million, fully focusing the pipeline on Avalo’s promising immunology assetsDisclosed improved cash of approximately $10.2 million as of September 30, 2023 WAYNE, Pa. and ROCKVILLE, Md., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and financial results for the third quarter of 2023.